Multiple Myeloma | Norton Healthcare

Indication: Multiple Myeloma

A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma

t(11;14)-Positive Relapsed or Refractory

Sub-indication: mutiple myeloma with t(11;14)

Line of Therapy: third line

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: AbbVie

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.